BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
358.71
+0.60 (+0.17%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close358.11
Open358.35
Bid358.00 x 100
Ask359.90 x 100
Day's Range356.61 - 360.50
52 Week Range249.17 - 370.57
Volume1,647,935
Avg. Volume1,851,755
Market Cap75.691B
Beta1.21
PE Ratio (TTM)25.64
EPS (TTM)13.99
Earnings DateJul 24, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est367.08
Trade prices are not sourced from all markets
  • Final Trade: BIIB, TTWO & more
    CNBC Videos4 days ago

    Final Trade: BIIB, TTWO & more

    The "Fast Money" traders share their final trades of the day, including Biogen, Take-Two Interactive, American Express and Huntsman.

  • Biogen is Sarissa's Alex Denner's best idea at Delivering...
    CNBC Videos4 days ago

    Biogen is Sarissa's Alex Denner's best idea at Delivering...

    CNBC's Dominic Chu reports on Sarissa Capital Management's Alex Denner presenting his best investment ideas at Delivering Alpha.

  • CNBC11 hours ago

    Top Alzheimer’s researchers report near-100 drugs in key trials, and hopes for a breakthrough

    The search for a drug to treat Alzheimer's disease, the most common form of dementia, has been marked by clinical trial failures. The dementia scientists are worried that the history of failures has left the health-care system unprepared to diagnose and treat patients if a breakthrough Alzheimer's drug becomes available. Fifty million people worldwide and six million Americans are living with Alzheimer’s, and the number is expected to rise sharply.

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markityesterday

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIB

  • GlobeNewswire2 days ago

    Biogen to Host Investor Webcast to Discuss Alzheimer’s Disease Portfolio on July 25, 2018

    Biogen (BIIB) today announced it will host a live webcast providing a Q&A session related to its Alzheimer’s disease investigational therapies on Wednesday, July 25, 2018.  The live webcast will begin at 6:00 p.m. ET/5:00 p.m. CT on July 25, 2018, with Alfred Sandrock, Jr., M.D., Ph.D., executive vice president and chief medical officer at Biogen, and Samantha Budd Haeberlein, Ph.D., vice president, Alzheimer’s disease, dementia and movement disorders, late stage clinical development at Biogen. To access the live webcast, please go to the Investors section of Biogen’s website at www.biogen.com/investors.  Following the live webcast, an archived version of the call will be available on the website.

  • TheStreet.com2 days ago

    Prepare for Volatility Around Biogen Ahead of Alzheimer's Presentation: Leerink

    It's time to temper the excitement around Biogen Inc. Leerink Partners analyst Geoffrey Porges warned the Cambridge, Mass.-based biotech company's shares could experience "tremendous volatility" ahead of the release of detailed results from Biogen's Alzheimer's drug BAN2401 at the Alzheimer's Association International Conference meeting in Chicago on Wednesday, July 25. Porges estimated that the stock could fall by $20 to $334 if results showed a marginal difference in cognitive decline, but could gain as much as $40 to $393 a share if the data show substantial decreases, he wrote in a note.

  • Benzinga2 days ago

    Jim Cramer Advises His Viewers On BlackRock, Target And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said Biogen Inc (NASDAQ: BIIB ) could double if it meets its endpoints and it could lose 40 percent if it doesn't meet them. The company failed ...

  • ACCESSWIRE3 days ago

    Wired News – Biogen to Present Data from Alzheimer’s Disease Clinical Development Portfolio at AAIC in Chicago

    LONDON, UK / ACCESSWIRE / July 20, 2018 / If you want access to our free research report on Biogen Inc. (NASDAQ: BIIB), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BIIB as the Company’s latest news hit the wire. On July 18, 2018, the Company declared that it will present data from its Alzheimer’s disease clinical development portfolio at the upcoming Alzheimer’s Association International Conference (AAIC), to be held in Chicago on July 22-26, 2018. Active-Investors.com is currently working on the research report for Orgenesis Inc. (NASDAQ: ORGS), which also belongs to the Healthcare sector as the Company Biogen.

  • Here's Why AC Immune SA Rose as Much as 21.6% Today
    Motley Fool3 days ago

    Here's Why AC Immune SA Rose as Much as 21.6% Today

    The early-stage biopharma announced more details about a share offering to raise much-needed capital.

  • Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?
    Zacks3 days ago

    Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

    On the Q2 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance

  • Benzinga3 days ago

    Delivering Alpha 2018: Everything You Need To Know

    The Delivering Alpha 2018 conference took place Wednesday in New York, and this year’s event included a number of Wall Street heavy-hitters. Benzinga Pro reported live from Delivering Alpha all day long, ...

  • Trending: Disillusioned Investors Punish Netflix Stock Due to Subscriber Shortfall
    ETF Database3 days ago

    Trending: Disillusioned Investors Punish Netflix Stock Due to Subscriber Shortfall

    Netflix failed to meet market expectations, posting disappointing subscriber adds and lowering third-quarter targets.

  • InvestorPlace4 days ago

    New Drugs and Expected Growth Could Trigger a Recovery for Celgene Stock

    Celgene (NASDAQ:CELG) continues to struggle. A series of self-inflicted wounds and a looming patent expiration plague the Summit, New Jersey-based firm. As a result, CELG stock has lost more than 40% of its value since its October 2017 high.

  • TheStreet.com4 days ago

    5 Big Biotech Stories to Watch

    President Trump's attack on large pharma companies over drug prices might have grabbed headlines recently, but that shouldn't distract from the firms and drugs that have been driving change and innovation in the biotech industry. Here's a rundown of some of the news from small to large companies in the past few weeks that could have a big impact on the biotechnology and pharmaceutical sectors. 1. Biogen's Alzheimer's drug trial results show promise Curing Alzheimer's disease has frustrated the healthcare industry for years after numerous failed attempts have been made to find a treatment, but Biogen Inc.

  • CNBC4 days ago

    Hedge fund manager and Icahn protege is bullish on three drug stocks including Biogen

    Sarissa Capital Management chief investment officer Alex Denner highlighted Biogen as one of his top stock picks Wednesday. Sarissa Capital Management chief investment officer Alex Denner highlighted Biogen BIIB as one of his top stock picks at the Delivering Alpha Conference in New York on Wednesday.

  • GlobeNewswire4 days ago

    Data to be Presented From Biogen's Alzheimer's Disease Clinical Development Portfolio at the 2018 Alzheimer's Association International Conference (AAIC)

    Ongoing Alzheimer`s disease research programs target possible causes of the disease through multiple modalities Data to be presented from Alzheimer`s disease clinical development portfolio including aducanumab, ...

  • GlobeNewswire4 days ago

    Data to be Presented From Biogen’s Alzheimer’s Disease Clinical Development Portfolio at the 2018 Alzheimer’s Association International Conference (AAIC)

    Biogen (BIIB) announced it will present data from its Alzheimer’s disease clinical development portfolio at the upcoming Alzheimer’s Association International Conference (AAIC) in Chicago (July 22-26). Data being presented are part of Biogen’s research programs targeting several of the identified causes of Alzheimer’s disease, focusing on early-stage disease.

  • The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon
    Zacks6 days ago

    The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon

    The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon

  • Better Buy: Biogen Inc. vs. Amgen
    Motley Fool7 days ago

    Better Buy: Biogen Inc. vs. Amgen

    Biogen and Amgen have been two of the best performing biotechs for a decade. But one stock clearly has an easier path toward value creation.

  • Motley Fool9 days ago

    Are We on the Cusp of a Big Alzheimer's Disease Breakthrough?

    One of Biogen's drugs could put us on a path to delaying disease progression.

  • Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom
    Zacks9 days ago

    Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom

    Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom

  • 5 Big Pharma Stocks Investors Love Right Now
    InvestorPlace9 days ago

    5 Big Pharma Stocks Investors Love Right Now

    News of positive clinical data for its Alzheimer’s study lifted the entire biotechnology sector. Oddly enough, markets largely ignored pharmaceutical stocks, choosing instead to invest in the riskier biotech sector. The following are Big Pharma stocks that should be on the radar of most investors.

  • Dopamine and the Weather, Part 2
    Zacks10 days ago

    Dopamine and the Weather, Part 2

    How technology changes human behavior and social rules, but not human nature and genetics???yet.

  • InvestorPlace10 days ago

    3 Real Risks That Could Make You Reconsider Buying Celgene Stock

    Celgene Corporation (NASDAQ:CELG) stock looks attractive here, for a number of reasons. Celgene stock has sold off, losing about 43% of its value. Celgene touched a four-year low in May before a recent rebound. The decline leaves Celgene looking awfully cheap, at a little over 8.3x 2019 consensus EPS estimates.

  • Is Ionis Pharmaceuticals, Inc. a Buy?
    Motley Fool10 days ago

    Is Ionis Pharmaceuticals, Inc. a Buy?

    One successful drug on the market. Two potential approvals on the way. Six big partners. But do the numbers add up to buying Ionis right now?